NPA
NPA Releases Agenda for The Big Natural
Washington, D.C.—The Natural Products Association (NPA) released the agenda for The Big Natural, which takes place September 11-12, right after their lobbying Day on...
More Tariffs Imposed on Chinese Imports; China, Industry React
Washington, D.C., and Beijing, China—President Trump has announced that he will impose a 10% tariff on the remaining $300 billion worth of untaxed imports...
Counterfeit Supplement Concerns at Amazon; NPA Points to SSCI to Protect Consumers
Washington, DC--The Natural Products Association (NPA) announced that it has offered to be a resource for Amazon after concerns emerged about counterfeit nutritional supplements....
Adherence and Label Literacy Key with New Supplement Facts Labels
Washington, D.C.—On July 18, the bipartisan, bicameral Dietary Supplement Caucus (DCS) held an educational briefing with help from the American Herbal Products Association (AHPA),...
NPA Submits Comments to FDA on NDIs and CBD
Washington, DC--The Natural Products Association (NPA) has filed comments with the Food and Drug Administration (FDA) regarding its review of “Responsible Innovation in Dietary...
Jim Emme to Speak at NPA’s The Big Natural
Washington, D.C.—Jim Emme, CEO of NOW Health Group and a member of the Natural Product Association’s (NPA) Board of Directors, will speak at NPA’s...
Congress Urges FDA To Move Forward With CBD Legalization
Washington, D.C.—Senator Ron Wyden (D-OR) urged FDA to promptly issue guidance that ensures the regulatory pathway Congress intended for the lawful use of CBD...
House Passes Amendment Designed to Ensure CBD is Regulated by FDA
Washington, DC--The Natural Products Association (NPA) announced earlier this week that it was seeking help from Congress to encourage the Food and Drug Administration...
FDA Warns Women Against Vinpocetine; NPA Alleges “Red Herring”
Washington, D.C.—FDA issued a statement warning women of childbearing age about use of vinpocetine, due to a recent report from the National Institute of...
FDA Cannabis/CBD Public Hearing: “FDA Does Not Have the Luxury Of Time”
Washington, D.C.—The Food and Drug Administration (FDA) held a public hearing on Friday looking for scientific data and information regarding cannabis and cannabis-derived compounds....
